Raymond James Financial reiterated their hold rating on shares of Nantkwest (NASDAQ:NK) in a research report report published on Monday.
NK has been the topic of a number of other reports. Zacks Investment Research upgraded Nantkwest from a hold rating to a buy rating and set a $4.50 target price on the stock in a research note on Tuesday, November 14th. Citigroup set a $3.00 target price on Nantkwest and gave the company a sell rating in a research note on Monday, August 14th. Finally, BidaskClub cut shares of Nantkwest from a sell rating to a strong sell rating in a research note on Friday, September 22nd. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The stock has a consensus rating of Hold and a consensus target price of $5.13.
Nantkwest (NASDAQ NK) traded up $0.05 during mid-day trading on Monday, reaching $5.05. The company’s stock had a trading volume of 238,300 shares, compared to its average volume of 366,612. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01. Nantkwest has a 12 month low of $2.71 and a 12 month high of $8.45.
Several hedge funds and other institutional investors have recently modified their holdings of NK. Renaissance Technologies LLC raised its stake in shares of Nantkwest by 1,884.1% during the first quarter. Renaissance Technologies LLC now owns 486,100 shares of the biotechnology company’s stock valued at $1,726,000 after purchasing an additional 461,600 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Nantkwest by 8.4% during the first quarter. Vanguard Group Inc. now owns 2,082,706 shares of the biotechnology company’s stock valued at $7,394,000 after purchasing an additional 160,510 shares in the last quarter. Northern Trust Corp raised its stake in shares of Nantkwest by 67.8% during the second quarter. Northern Trust Corp now owns 304,062 shares of the biotechnology company’s stock valued at $2,308,000 after purchasing an additional 122,906 shares in the last quarter. State Street Corp raised its stake in shares of Nantkwest by 52.9% during the second quarter. State Street Corp now owns 341,007 shares of the biotechnology company’s stock valued at $2,589,000 after purchasing an additional 117,946 shares in the last quarter. Finally, Alps Advisors Inc. bought a new stake in Nantkwest in the second quarter worth about $563,000. Institutional investors and hedge funds own 19.14% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Raymond James Financial Reaffirms Hold Rating for Nantkwest (NK)” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://sportsperspectives.com/2017/12/14/raymond-james-financial-reaffirms-hold-rating-for-nantkwest-nk.html.
Nantkwest Company Profile
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.